The court document further alleges that Novo Nordisk failed to warn the plaintiff about the risks of Ozempic, demonstrating negligence and deception in marketing, and a design defect
Have a baseline BMI (prior to any weight-loss treatment) of 30 or 25 with one or more previously diagnosed conditions: Controlled Type II Diabetes, Sleep Apnea, High Cholesterol, High Triglycerides, Prediabetes, High Blood Pressure, Heart disease, Osteoarthritis, Polycystic Ovarian Syndrome (PCOS), Non-alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease, Gastroesophageal Reflux Disease (GERD), Depression, Anxiety, Weight-Related Psychosocial Distress, Stroke, Coronary Artery Disease, Metabolic Syndrome, Insulin Resistance, Body Pain, Infertility, Hypothyroidism, Sexual Dysfunction
The train company can also offer assistance, such as providing a quiet area for self-administration or storing your medication in a refrigerated area
One of the most noted effects of GLP-1s like tirzepatide and semaglutide beyond their weight loss and blood sugar control abilities is how they help quiet food noise